NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03263429 |
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer |
Colorectal Cancer
Metastatic Colorectal Cancer
RAS Wild Type Colorectal Cancer
Refractory Colorectal Cancer |
Drug: Glutaminase Inhibitor CB-839|Biological: Panitumumab|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Device: Imaging with 18F-FSPG PET/CT scans |
Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Calithera Biosciences, Inc |
Phase 1
Phase 2 |
NCT03259503 |
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
Lymphoma |
Drug: Palifermin|Drug: Olaparib|Drug: Vorinostat|Drug: Dexamethasone|Drug: Rituximab|Drug: Caphosol|Drug: Glutamine|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Pyridoxine|Procedure: Autologous Stem-Cell Transplant|Drug: G-CSF |
M.D. Anderson Cancer Center|AstraZeneca |
Phase 1
Phase 2 |
NCT03258554 |
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin |
Head and Neck Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7... |
Biological: Cetuximab|Biological: Durvalumab|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Other: Questionnaire Administration |
National Cancer Institute (NCI) |
Phase 2
Phase 3 |
NCT03262779 |
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
Biological: combination nivolumab and ipilimumab |
Yale University|Bristol-Myers Squibb |
Phase 2 |
NCT03262103 |
Neoadjuvant Hiltonol? (PolyICLC) for Prostate Cancer |
Prostate Cancer |
Biological: Intratumoral (IT) Poly ICLC 0.5 mg|Biological: Intratumoral (IT) Poly ICLC 1.0 mg|Biological: Intramuscular (IM) Poly ICLC|Procedure: Radical Prostatectomy |
Ashutosh Kumar Tewari|Oncovir, Inc.|Icahn School of Medicine at Mount Sinai |
Phase 1 |
NCT03258593 |
Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies |
Urinary Bladder Neoplasms |
Drug: Durvalumab
Drug: Vicinium |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03258567 |
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas |
Epstein-Barr Virus Infections
Lymphoma |
Drug: Nivolumab |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Phase 2 |